Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

Similar articles for PubMed (Select 25009009)

1.

Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer.

Hashimoto K, Tsuda H, Koizumi F, Shimizu C, Yonemori K, Ando M, Kodaira M, Yunokawa M, Fujiwara Y, Tamura K.

Ann Oncol. 2014 Oct;25(10):1973-9. doi: 10.1093/annonc/mdu247. Epub 2014 Jul 9.

PMID:
25009009
2.

Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.

Sukawa Y, Yamamoto H, Nosho K, Kunimoto H, Suzuki H, Adachi Y, Nakazawa M, Nobuoka T, Kawayama M, Mikami M, Matsuno T, Hasegawa T, Hirata K, Imai K, Shinomura Y.

World J Gastroenterol. 2012 Dec 7;18(45):6577-86. doi: 10.3748/wjg.v18.i45.6577.

3.

PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.

Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van Diest PJ, Linn SC.

Breast Cancer Res. 2014 Jan 27;16(1):R13. doi: 10.1186/bcr3606.

4.

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

Breast Cancer Res. 2009;11(1):R11. doi: 10.1186/bcr2230. Epub 2009 Feb 24.

5.

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients.

Machleidt A, Buchholz S, Diermeier-Daucher S, Zeman F, Ortmann O, Brockhoff G.

BMC Cancer. 2013 Sep 24;13:437. doi: 10.1186/1471-2407-13-437.

6.

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.

Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA.

Breast Cancer Res. 2014 Aug 8;16(4):406. doi: 10.1186/s13058-014-0406-x.

7.

Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.

Huang L, Chen T, Chen C, Chen S, Liu Y, Wu J, Shao Z.

World J Surg Oncol. 2013 Nov 30;11:307. doi: 10.1186/1477-7819-11-307.

8.

Clinical implication of leucine zipper/EF hand-containing transmembrane-1 overexpression in the prognosis of triple-negative breast cancer.

Wang CA, Liu Q, Chen Y, Liu S, Xu J, Cui X, Zhang Y, Piao L.

Exp Mol Pathol. 2015 Apr;98(2):254-9. doi: 10.1016/j.yexmp.2014.12.012. Epub 2015 Jan 21.

PMID:
25617527
9.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

10.

Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology.

Jung HA, Park YH, Kim M, Kim S, Chang WJ, Choi MK, Hong JY, Kim SW, Kil WH, Lee JE, Nam SJ, Ahn JS, Im YH.

Tumour Biol. 2015 Feb;36(2):1073-9. doi: 10.1007/s13277-014-2730-2. Epub 2014 Oct 19.

PMID:
25326808
11.

The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.

Jansson S, Bendahl PO, Grabau DA, Falck AK, Fernö M, Aaltonen K, Rydén L.

PLoS One. 2014 Jul 15;9(7):e102176. doi: 10.1371/journal.pone.0102176. eCollection 2014.

12.

Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases.

Schmitz KJ, Otterbach F, Callies R, Levkau B, Hölscher M, Hoffmann O, Grabellus F, Kimmig R, Schmid KW, Baba HA.

Mod Pathol. 2004 Jan;17(1):15-21.

13.

Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings.

Abdel-Fatah TM, Perry C, Dickinson P, Ball G, Moseley P, Madhusudan S, Ellis IO, Chan SY.

Ann Oncol. 2013 Nov;24(11):2801-7. doi: 10.1093/annonc/mdt277. Epub 2013 Aug 1.

14.

Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.

Hosonaga M, Arima Y, Sugihara E, Kohno N, Saya H.

Cancer Sci. 2014 Jul;105(7):779-87. doi: 10.1111/cas.12427. Epub 2014 Jun 2.

PMID:
24754246
15.

Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression.

Schmidt G, Meyberg-Solomayer G, Gerlinger C, Juhasz-Böss I, Herr D, Rody A, Liedtke C, Solomayer EF.

Arch Gynecol Obstet. 2014 Dec;290(6):1221-9. doi: 10.1007/s00404-014-3331-4. Epub 2014 Jul 11.

PMID:
25012601
16.

Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.

Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Ellis IO, Green AR.

Breast Cancer Res Treat. 2011 Jun;127(2):407-16. doi: 10.1007/s10549-010-1012-y. Epub 2010 Jul 9.

PMID:
20617378
17.

A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.

Ma F, Ding X, Fan Y, Ying J, Zheng S, Lu N, Xu B.

PLoS One. 2014 Nov 13;9(11):e112765. doi: 10.1371/journal.pone.0112765. eCollection 2014.

18.

A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.

Park YH, Jung HH, Do IG, Cho EY, Sohn I, Jung SH, Kil WH, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH.

Int J Cancer. 2015 Apr 15;136(8):1976-84. doi: 10.1002/ijc.29233. Epub 2014 Dec 24.

PMID:
25537444
19.
20.

Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?

Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F.

BMC Cancer. 2011 Jul 15;11:299. doi: 10.1186/1471-2407-11-299.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk